Lion Point Capital, LP

Lion Point Capital, LP reported 34 holdings worth US$17.3M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Lion Point Capital, LP reported 34 holdings worth US$17.3M as of Sep 30, 2026. Largest: Cue Biopharma, Inc., Praxis Precision Medicines, Inc. and Fennec Pharmaceuticals Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
34
Value as reported
US$17.3M

The filing in full

CompanySharesValue as reported% of portfolio
Cue Biopharma, Inc.52,928US$1.37M7.9%
Praxis Precision Medicines, Inc.4,450US$1.3M7.5%
Fennec Pharmaceuticals Inc.112KUS$1.2M6.9%
COMPASS Pathways Plc80,000US$995K5.8%
Geron Corporation578KUS$711K4.1%
Milestone Pharmaceuticals Inc.820KUS$710K4.1%
Biohaven Ltd.51,700US$690K4.0%
Syndax Pharmaceuticals, Inc.36,000US$677K3.9%
Benitec Biopharma Inc.62,000US$620K3.6%
Disc Medicine, Inc.8,100US$530K3.1%
Sarepta Therapeutics, Inc.28,500US$519K3.0%
Kura Oncology, Inc.46,000US$493K2.9%
Viatris Inc.27,700US$491K2.8%
Ardelyx, Inc.129KUS$440K2.5%
Edgewise Therapeutics, Inc.9,100US$369K2.1%
Azenta, Inc.9,700US$338K2.0%
Pacira BioSciences, Inc.13,500US$338K2.0%
Humacyte, Inc.650KUS$337K1.9%
BridgeBio Pharma, Inc.5,000US$329K1.9%
Janux Therapeutics, Inc.19,000US$328K1.9%
Dyne Therapeutics, Inc.18,000US$290K1.7%
Jasper Therapeutics, Inc.465KUS$270K1.6%
Mineralys Therapeutics, Inc.10,500US$264K1.5%
Rocket Pharmaceuticals, Inc.86,000US$226K1.3%
Regenxbio Inc.26,600US$200K1.2%
Innoviva, Inc.8,200US$174K1.0%
Arcutis Biotherapeutics, Inc.5,250US$139K0.80%
Innate Pharma SA Class A81,151US$132K0.77%
Seres Therapeutics, Inc.31,570US$106K0.61%
Spruce Biosciences, Inc.1,000US$48,5800.28%
Lantheus Holdings, Inc.0US$00.00%

Source

Download original · View original at SEC

Related